Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Oreja-Guevara C, Gómez-Estévez I, Agüado García L, Martín Martínez J, Gómez Gutiérrez M, Gascón Giménez F, Agüera Morales E, Meca-Lallana V, Barrero Hernández FJ, González Quintanilla V, Romero Pinel L, Delgado Gil V, Durán Ferreras E, Blasco Quílez R, Meca-Lallana J, Landete Pascual L, Aladro-Benito Y, Boyero Durán S, Gracia Gil J, Caminero Rodríguez AB, Cano Orgaz AT, Eichau Madueño S, Querol Pascual MR, Otano Martínez M, Alonso Torres AM, Calles Hernández C, López Real A, Ares Luque A, Lorenzo González JR, Gómez Vicente L, Díaz Sánchez M.

Open source

DOI: 10.1177/17562864261472650
Published: 2026-08-13
Container: Ther Adv Neurol Disord
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/17562864261472650,
  title = {Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.},
  author = {Oreja-Guevara C and  Gómez-Estévez I and  Agüado García L and  Martín Martínez J and  Gómez Gutiérrez M and  Gascón Giménez F and  Agüera Morales E and  Meca-Lallana V and  Barrero Hernández FJ and  González Quintanilla V and  Romero Pinel L and  Delgado Gil V and  Durán Ferreras E and  Blasco Quílez R and  Meca-Lallana J and  Landete Pascual L and  Aladro-Benito Y and  Boyero Durán S and  Gracia Gil J and  Caminero Rodríguez AB and  Cano Orgaz AT and  Eichau Madueño S and  Querol Pascual MR and  Otano Martínez M and  Alonso Torres AM and  Calles Hernández C and  López Real A and  Ares Luque A and  Lorenzo González JR and  Gómez Vicente L and  Díaz Sánchez M.},
  year = {2026},
  journal = {Ther Adv Neurol Disord},
  doi = {10.1177/17562864261472650},
  url = {https://doi.org/10.1177/17562864261472650}
}

RIS

TY  - JOUR
TI  - Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.
AU  - Oreja-Guevara C
AU  -  Gómez-Estévez I
AU  -  Agüado García L
AU  -  Martín Martínez J
AU  -  Gómez Gutiérrez M
AU  -  Gascón Giménez F
AU  -  Agüera Morales E
AU  -  Meca-Lallana V
AU  -  Barrero Hernández FJ
AU  -  González Quintanilla V
AU  -  Romero Pinel L
AU  -  Delgado Gil V
AU  -  Durán Ferreras E
AU  -  Blasco Quílez R
AU  -  Meca-Lallana J
AU  -  Landete Pascual L
AU  -  Aladro-Benito Y
AU  -  Boyero Durán S
AU  -  Gracia Gil J
AU  -  Caminero Rodríguez AB
AU  -  Cano Orgaz AT
AU  -  Eichau Madueño S
AU  -  Querol Pascual MR
AU  -  Otano Martínez M
AU  -  Alonso Torres AM
AU  -  Calles Hernández C
AU  -  López Real A
AU  -  Ares Luque A
AU  -  Lorenzo González JR
AU  -  Gómez Vicente L
AU  -  Díaz Sánchez M.
PY  - 2026
JO  - Ther Adv Neurol Disord
DO  - 10.1177/17562864261472650
UR  - https://doi.org/10.1177/17562864261472650
ER  -

APA

C, O., I, G., L, A. G., J, M. M., M, G. G., F, G. G., E, A. M., V, M., FJ, B. H., V, G. Q., L, R. P., V, D. G., E, D. F., R, B. Q., J, M., L, L. P., Y, A., S, B. D., J, G. G., AB, C. R., AT, C. O., S, E. M., MR, Q. P., M, O. M., AM, A. T., C, C. H., A, L. R., A, A. L., JR, L. G., L, G. V., & M., D. S. (2026). Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.. Ther Adv Neurol Disord. https://doi.org/10.1177/17562864261472650

Source records

europe-pmc · retrieved 2026-09-25T12:48:09.992Z
doaj · retrieved 2026-09-25T12:48:10.001Z